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Background. Catheter-line-associated bloodstream infection (CLABSI) is a serious complication of patients on long-term central venous catheters (CVC). Taurolidine-citrate solution (TCS) is a catheter-lock solution with broad-spectrum antimicrobial action that prevents biofilm formation. The aim of this study was to evaluate the efficacy of TCS in reducing CLABSI rate in pediatric patients with longterm CVC at a tertiary children's hospital.
Methods. This was an open-label trial of hematology-oncology (H/O) and gastrointestinal (GI) inpatients with the following inclusion criteria: Pediatric patients < 17 years of age, at least 1 previous CLABSI, required long-term CVC, e.g., long-term parenteral nutrition or undergoing chemotherapy for malignancy and have a minimum dwell time of at least 8 hours for TCS. The period of surveillance was from each patient's first CVC insertion till December 14, 2017 or discontinuation of TCS. CLABSI was calculated based on the number of CVC-associated BSI per 1,000 catheter-days. Statistics were derived using SPSS 19.0 and the student T-test for paired samples and nonparametric Wilcoxon analysis for two-related-samples test with a P value of < 0.05. OpenEpi v3.01 was used to compare 2 person-time rates and rate ratios with 95% confidence intervals.
Results. Thirty-four patients were recruited with a median age of 3.4 years (IQR 1.5-10.1 years). H/O patients constituted 58.8% (n = 20) and GI patients 41.2% (n = 14). The majority of CVC were Hickman line (n = 16, 47.1%) followed by Port-a-Cath (n = 8, 23.5%) and PICC (n = 10, 29.4%). The median duration of TCS usage was 138 days (IQR 62.50-307.25 days). The longest duration of TCS was 1737 days (4.8 years). Median pre-and post-TCS CLABSI rates for the whole cohort, H/O and GI patients were 14.92 ± 13.50 and 2.65 ± 4.31 (P < 0.001); 16.55 ± 12.96 and 2.81 ± 4.66 (P < 0.001); 12.59 ± 14.39 and 2.42 ± 3.91 (P = 0.011) per 1000 catheter days respectively. For the whole cohort, pre and post-TCS rate ratio was 0.20 (95% CI 0.12-0.33, P < 0.001). TCS reduced markedly the risk of CLABSI for the whole cohort by 80%; for H/O patients by 79% and GI patients by 88%.
Conclusion. Taurolidine-citrate solution was highly successful in reducing CLABSI rates by 80% in patients on long-term CVC with high baseline CLABSI rates.
Disclosures. All authors: No reported disclosures. Background. Indwelling urinary catheters (IUC) may cause inflammation and colonization, decreasing the diagnostic yield of urinalysis and urine cultures (UC). Indiscriminate testing can lead to misinterpretation of positive results as a catheter associated urinary tract infection (CAUTI), increasing antibiotic use and CAUTI rates. We studied the burden of UC and implemented a UC stewardship initiative (UCSI) as part of a comprehensive CAUTI reduction program.
Changing the Culture: A Quasi-Experimental Study Assessing the Burden of Urine Cultures and the Impact of Stewardship of Testing in an Urban
Methods. A retrospective review of cases with IUC and positive UC in 2014 was performed. UCSI was implemented in March 2017 (Figure 1 ). Nursing staff were instructed to contact the infectious diseases physician when UC from IUC were ordered. Cases were reviewed and, if no UC indication based on IDSA guidelines was met, cultures were discontinued after conferring with ordering physician. Twelve months pre-and post-intervention data were collected; including case description, catheter days, UC ordered, alternative cause of fever, and recommendations.
Results. The pre-USCI cohort had 23 UC in 19 cases. One UC (4%) met indication (Figure 2 ). Three (16%) met NHSN criteria for CAUTI and did not meet UC indication. The USCI cohort had 21 UC orders in 13 cases. Most UC did not meet indication and were cancelled (90%, 19/21). Alternative causes for fever were found in all cases with cancelled UC orders (19/19), including pneumonitis, pneumonia, pancreatitis and tuberculosis. Antimicrobials were used in 53% (7/13). UC orders per hospitalization ranged 1-4 (average 1.7). IUC days ranged from 3 to 18 days (average 8). In both cohorts, UC with indication (3) did not meet NHSN criteria for CAUTI and did not receive antimicrobials. 
Conclusion.
Patients with IUC frequently underwent UC without evidence-based indications. This may lead clinicians down the wrong diagnostic path and contribute to antimicrobial use. Critically ill patients with inflammatory conditions are at high risk of UC testing. USCI is a cost-effective intervention that reduced indiscriminate testing, antibiotic use and CAUTIs. USCI can play an important role in CAUTI prevention strategies and antibiotic stewardship programs.
Disclosures. All authors: No reported disclosures. Background. Catheter-associated urinary tract infections (CAUTI) negatively impact patient morbidity, mortality and insurance reimbursement rates in acute care hospitals. Since CAUTIs are solely defined by the National Health and Safety Network (NHSN), not by clinical definition or urinalysis (UA) result, eliminating unnecessary urine cultures will improve the accuracy of reportable CAUTI rates. Negative UA can accurately detect false-positive (FP) CAUTIs in patients with 100% negative predictive value.
Assessing the Accuracy of Catheter-Associated Urinary Tract Infections (CAUTI) Identification Using Urinalysis Results
Methods. We conducted a retrospective analysis of 2017 CAUTIs reported from two acute care hospitals (A and B) to determine the effectiveness of a UA screening protocol and the distribution of FPs. Hospital B implemented a UA screening protocol requiring a UA prior to urine culture. Hospital A relied solely on microbiology cultures. FPs were identified by a negative UA result, the absence of bacteria, performed on the same or prior day to the urine culture that resulted in a CAUTI.
Results. Our analysis showed that 13 (34%) of the 38 reported CAUTIs with an associated UA result at hospital A were FPs. Patients with a UC line duration >7 days had a CAUTI FP rate of 62% compared with 27% of those with a line duration between 3 and 7 days (Figure 1) (OR 4.6, CI: 0.9, 23.7 , P = 0.09). Hospital A (no screening protocol) was 37.4 times more likely to have a FP CAUTI compared with hospital B (UA screening protocol) (CI: 2.1, 660.6; P < 0.0004).
Conclusion. A positive culture with a negative UA is indicative of asymptomatic colonization, not true infection. Preventing FP CAUTIs would result in a 34% reduction in CAUTI rates at hospital A, placing the hospital in a better reimbursement benchmark (Figure 2 ). Interventions include: (1) A best practice alert in the patient's electronic medical record that can be used to notify the providers to re-evaluate patients with UCs in place ≥ 5 days, (2) A screening protocol that requires a UA order prior to/during specimen collection and prevents processing of urine cultures with a negative UA. In patients with UCs, a protocol should be implemented to reduce FP CAUTIs to better understand the true epidemiology of CAUTIs in hospitals and increase reporting accuracy.
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